NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells - PubMed (original) (raw)
. 2000 Sep 1;60(17):4946-52.
Affiliations
- PMID: 10987311
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells
H M Zarour et al. Cancer Res. 2000.
Abstract
The NY-ESO-1 gene is expressed by a range of human tumors and encodes HLA-A2-restricted melanoma peptides recognized by CD8+ CTLs. Here we report that the NY-ESO-1 gene also encodes two overlapping, but non-cross-reactive, HLA-DRB1*0401-presented peptides that are recognized by CD4+ T cells. The NY-ESO-1(119-143) peptide was able to induce specific CD4+ T cells in vitro from both an HLA-DRB1*0401+ normal donor and an HLA-DRB1*0401+ patient with melanoma. Bulk and cloned CD4+ T cells produced IFN-gamma specifically in response to, and also lysed, T2.DR4 cells pulsed with peptide NY-ESO-1(119-143) and the autologous tumor cell line, but not a DRB1*0401+ melanoma cell line that does not express NY-ESO-1. Interestingly, the NY-ESO119-143 peptide contains two overlapping putative "core" epitopes recognized by non-cross-reactive anti-NY-ESO-1(119-143) CD4+ T-cell clones. Taken together, these data support the use of this novel DR4-restricted tumor peptide, NY-ESO-1(119-143), or its two "sub-epitopes" in immunotherapeutic trials designed to generate or enhance specific CD4+ T-cell responses against tumors expressing NY-ESO-1 in vivo.
Similar articles
- NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM. Zarour HM, et al. Cancer Res. 2002 Jan 1;62(1):213-8. Cancer Res. 2002. PMID: 11782380 - The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
Mandic M, Almunia C, Vicel S, Gillet D, Janjic B, Coval K, Maillere B, Kirkwood JM, Zarour HM. Mandic M, et al. Cancer Res. 2003 Oct 1;63(19):6506-15. Cancer Res. 2003. PMID: 14559844 - In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M, Nakamura H, Shiku H, Gnjatic S, Murphy R, Hiramatsu Y, Old LJ, Nakayama E. Hasegawa K, et al. Clin Cancer Res. 2006 Mar 15;12(6):1921-7. doi: 10.1158/1078-0432.CCR-05-1900. Clin Cancer Res. 2006. PMID: 16551878 - Vaccination for malignant melanoma: recent developments.
Jäger D, Jäger E, Knuth A. Jäger D, et al. Oncology. 2001;60(1):1-7. doi: 10.1159/000055289. Oncology. 2001. PMID: 11150901 Review. - Hunting down factor VIII in the immunopeptidome.
Hartholt RB, Peyron I, Voorberg J. Hartholt RB, et al. Cell Immunol. 2016 Mar;301:59-64. doi: 10.1016/j.cellimm.2015.11.001. Epub 2015 Nov 5. Cell Immunol. 2016. PMID: 26610639 Review.
Cited by
- NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.
Alsalloum A, Shevchenko JA, Sennikov S. Alsalloum A, et al. Clin Transl Med. 2024 Sep;14(9):e70020. doi: 10.1002/ctm2.70020. Clin Transl Med. 2024. PMID: 39275923 Free PMC article. Review. - GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.
Hathaway-Schrader JD, Norton D, Hastings K, Doonan BP, Fritz ST, Bethard JR, Blum JS, Haque A. Hathaway-Schrader JD, et al. Int J Mol Sci. 2022 Jan 19;23(3):1066. doi: 10.3390/ijms23031066. Int J Mol Sci. 2022. PMID: 35162988 Free PMC article. - Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions.
Tay BQ, Wright Q, Ladwa R, Perry C, Leggatt G, Simpson F, Wells JW, Panizza BJ, Frazer IH, Cruz JLG. Tay BQ, et al. Vaccines (Basel). 2021 May 20;9(5):535. doi: 10.3390/vaccines9050535. Vaccines (Basel). 2021. PMID: 34065557 Free PMC article. Review. - Cancer Vaccines: Antigen Selection Strategy.
Zhao Y, Baldin AV, Isayev O, Werner J, Zamyatnin AA Jr, Bazhin AV. Zhao Y, et al. Vaccines (Basel). 2021 Jan 25;9(2):85. doi: 10.3390/vaccines9020085. Vaccines (Basel). 2021. PMID: 33503926 Free PMC article. Review. - IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM, Ka M, Pagliano O, Menna C, Ding Q, DeBlasio R, Sanders C, Hou J, Li XY, Ferrone S, Davar D, Kirkwood JM, Johnston RJ, Korman AJ, Smyth MJ, Zarour HM. Chauvin JM, et al. Clin Cancer Res. 2020 Oct 15;26(20):5520-5533. doi: 10.1158/1078-0432.CCR-20-0575. Epub 2020 Jun 26. Clin Cancer Res. 2020. PMID: 32591463 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials